Non-volitional assessment of skeletal muscle strength in patients with chronic obstructive pulmonary disease

W D-C Man, M G G Soliman, D Nikoletou, M L Harris, G F Rafferty, N Mustfa, M I Polkey, J Moxham

Background: Although quadriceps weakness is well recognised in chronic obstructive pulmonary disease (COPD), the aetiology remains unknown. In disabled patients the quadriceps is a particularly underused muscle and may not reflect skeletal muscle function as a whole. Loss of muscle function is likely to be equally distributed if the underlying pathology is a systemic abnormality. Conversely, if deconditioning and disuse are the principal aetiological factors, weakness would be most marked in the lower limb muscles.

Methods: The non-volitional technique of supramaximal magnetic stimulation was used to assess twitch tensions of the adductor pollicis, quadriceps, and diaphragm muscles (TwAP, TwQ, and TwPdi) in 22 stable non-weight losing COPD patients and 18 elderly controls.

Results: Mean (SD) TwQ tension was reduced in the COPD patients (7.1 (2.2) kg vs 10.0 (2.7) kg; 95% confidence intervals (CI) –4.4 to –1.4; p<0.001). Neither TwAP nor TwPdi (when corrected for lung volume) differed significantly between patients and controls (mean (SD) TwAP 6.52 (1.90) N for COPD patients and 6.80 (1.99) N for controls (95% CI –1.5 to 0.97; p=0.65; TwPdi 23.0 (5.6) cm H2O for COPD patients and 23.5 (5.2) cm H2O for controls (95% CI –4.5 to 3.5; p=0.81).

Conclusions: The strength of the adductor pollicis muscle (and the diaphragm) is normal in patients with stable COPD whereas quadriceps strength is substantially reduced. Disuse may be the principal factor in the development of skeletal muscle weakness in COPD, but a systemic process preferentially affecting the proximal muscles cannot be excluded.

METHODS
Twenty two outpatients with stable COPD were recruited from a respiratory clinic. Inclusion criteria included a baseline forced expiratory volume in 1 second (FEV1) <50% predicted, ratio of FEV1 to vital capacity (VC) of 60% or less, <10% improvement in FEV1 following a bronchodilator trial, at least 20 pack years of smoking, and no infective exacerbation in the preceding 4 weeks. Drug treatment included inhaled short acting β agonist (n=22), inhaled anticholinergic (n=14),...
inhaled long acting β2 agonist (n=12), inhaled corticosteroid (n=11), maintenance oral corticosteroids (n=2), oral theophylline (n=1), and long term oxygen therapy (n=1). Eighteen healthy elderly volunteers served as controls. All study participants were free from cardiac, rheumatological, or neuromuscular disorders that could limit mobility or reduce muscle strength. The local research ethics committee of King’s College Hospital approved the protocol and all participants gave informed consent.

Baseline spirometric parameters, transfer factor using the single breath method (Masterscreen PFT, Jaeger, Hoechberg, Germany), lung volumes obtained from body plethysmography (Auto-link, Morgan Medical, Gillingham, Kent, UK), and arterialised carlobe blood gases were measured in all subjects. Fat free mass (FFM) was determined in 20 patients and 12 controls by bioelectrical impedance analysis using a Bodystat (Bodystat Ltd, Douglas, UK) and disease and age specific controls by bioelectrical impedance analysis using a Bodystat (Bodystat Ltd, Douglas, UK).

Table 1  Anthropometric and lung function measurements in study participants

<table>
<thead>
<tr>
<th>Measure</th>
<th>Healthy elderly (n=18)</th>
<th>COPD patients (n=22)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>74.6 [6.3]</td>
<td>68.6 [8.9]</td>
<td>0.02</td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.66 [0.13]</td>
<td>1.67 [0.10]</td>
<td>0.91</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>72.7 [13.3]</td>
<td>72.8 [20.4]</td>
<td>0.99</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.2 [3.8]</td>
<td>26.2 [6.3]</td>
<td>0.98</td>
</tr>
<tr>
<td>Fat free mass (kg)</td>
<td>44.9 [9.0]</td>
<td>47.7 [10.4]</td>
<td>0.44</td>
</tr>
<tr>
<td>FEV₁ (litres)</td>
<td>2.6 [0.4]</td>
<td>0.9 [0.3]</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>FEV₁ (% pred)</td>
<td>101 [8]</td>
<td>39 [13]</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>FEV₁/VC (%)</td>
<td>75.6</td>
<td>37.6</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>TLC (% pred)</td>
<td>–</td>
<td>116.9 [18.0]</td>
<td>–</td>
</tr>
<tr>
<td>RV (% pred)</td>
<td>–</td>
<td>186.3 [48]</td>
<td>–</td>
</tr>
<tr>
<td>TLCO (% pred)</td>
<td>–</td>
<td>43.0 [15.5]</td>
<td>–</td>
</tr>
<tr>
<td>PaO₂ (kPa)</td>
<td>10.2 [1.0]</td>
<td>8.8 [1.4]</td>
<td>0.08</td>
</tr>
<tr>
<td>PaCO₂ (kPa)</td>
<td>5.5 [0.3]</td>
<td>5.4 [0.9]</td>
<td>0.81</td>
</tr>
</tbody>
</table>

Data expressed as mean (SD).

FEV₁=forced expiratory volume in 1 second; VC=vital capacity; TLC=total lung capacity; RV=residual volume; TLCO=carbon monoxide transfer factor; PaO₂, PaCO₂=arterial oxygen and carbon dioxide tensions.

Recording of adductor pollicis and quadriceps muscle function was studied in all subjects. Sixteen COPD patients and 15 healthy elderly controls also consented to the measurement of twitch transdiaphragmatic pressure (TwPdi).

Recording of adductor pollicis strength and electromyogram (EMG)

Adductor pollicis muscle function was studied using the technique previously described by Harris and colleagues with a modified handboard.7 Silver/silver chloride surface electromyogram (EMG) electrodes (Arbo Medical, CT, USA) were placed longitudinally over AP with the earth electrode placed on the tip of the index finger. The supinated hand and forearm were placed in a plastic arm splint that was secured to the handboard with velcro tapes to avoid rotation of the wrist, especially during stimulation. The splint was designed with a window on the medial aspect of the wrist and lower forearm to allow access to the ulnar nerve. The hand was further secured by a padded adjustable metal bar placed on the palm of the hand so that the fingers were comfortably flexed. The thumb was abducted and a metal loop was placed around the proximal phalanx. An inextensible metal chain connected the metal loop to a strain gauge (Strainstall range 0–100 kg) mounted to the back of the chair so that the strap ran perpendicular to the ankle and gauge. A 70 mm figure of eight coil head (powered by a double Magstim 200 stimulator) was positioned high in the femoral triangle just lateral to the femoral artery; the best spot was determined by minor positional adjustments during stimulations and marked. Potentiation was avoided and supramaximality determined as for the adductor pollicis muscle. Force and EMG were recorded with the same equipment and software set up as for the adductor pollicis.

Measurement of diaphragm strength

Transdiaphragmatic pressure (Pdi) was recorded by measuring oesophageal pressure (Poes) and gastric pressure (Pga) with a pair of conventionally placed polyethylene balloon catheters. Pressures were measured by differential pressure transducers (Validyne MP45, Validyne, Northridge, CA, USA). The signals from the transducers were connected to an analogue-digital board (NB-MIO-16, National Instruments, Austin, TX, USA) and recorded by a Macintosh Centis 650 computer using Labview 2.2 software (National Instruments). Twitch transdiaphragmatic pressures (TwPdi) were measured following bilateral anterolateral magnetic stimulation of the
Skeletal muscle strength in COPD

Adductor pollicis

\[ p = 0.65 \]

Quadriceps

\[ *p = 0.0005 \]

Diaphragm

\[ p = 0.81 \]

Figure 1 Scatterplots showing individual data and group means of non-volitional skeletal muscle strength in COPD and healthy elderly controls (HE). TwAP= twitch adductor pollicis tension; TwQ = twitch quadriceps tension; TwPdi = twitch transdiaphragmatic pressure corrected for lung volume.

DISCUSSION

This is the first study to compare the strength of the adductor pollicis muscle in COPD patients with age matched controls, and the first to non-volitionally assess the distribution of skeletal muscle weakness. The principal finding is that the strength of the adductor pollicis muscle (and diaphragm) is normal in patients with COPD, despite a substantial reduction in quadriceps strength. This indicates that, for the patients studied, a generalised myopathy does not exist in COPD and the adductor pollicis and diaphragm muscles behave in a different way from the quadriceps.

Methodology

MVC is often used for routine measurements of muscle strength. A true MVC relies on subject motivation, cooperation, and functional ability—factors particularly relevant in children, patients on intensive care units, those with cognitive difficulties, and those prevented from performing a true MVC by pain. However, even in well motivated subjects, submaximal muscle activation is common in routine clinical practice. There is therefore a need for non-volitional methods to assess muscle strength in clinical settings.

The true strength of a muscle is the maximum tetanic tension, which requires the delivery of trains of stimuli at different frequencies and construction of a force-frequency curve. For many muscles this is not tolerable in humans, hence techniques using single supramaximal stimuli have been developed. The tension generated enjoys a constant relationship with the maximal tetanic tension. Magnetic stimulation has recently been successfully introduced to the clinical and laboratory setting to assess the strength of the adductor pollicis and quadriceps muscles and the diaphragm. This form of stimulation is more reliable in ensuring supramaximality and is less painful than traditional electrical stimulation, so is more acceptable to patients; in this study magnetic stimulation was well tolerated by all participants.

Significance of findings

The strength of the adductor pollicis muscle in patients with COPD has not previously been compared with that of elderly control subjects, although Whittaker et al. reported that short term refeeding of malnourished COPD patients did not
improve adductor pollicis muscle function. By comparing their data with historical controls, Whittaker and colleagues concluded that adductor pollicis function was normal in COPD. The N2Pdi data in the present study support previous observations that, when corrected for lung volume, the contractility of the diaphragm is not reduced in COPD. 18 The preservation of strength in the diaphragm may be due to an involuntary “training” effect derived from the high work of breathing in patients with COPD. Consistent with this observation, the diaphragm muscle in COPD shows an increase in oxidative capacity, and there is a fast-to-slow fibre type transformation—that is, an increase in type 1 fibres—consistent with “overtraining”.

Although skeletal muscle dysfunction is well recognised in COPD, the relative contributions of systemic factors (such as inflammation, hypoxia, acidosis, malnutrition) and local muscle factors (such as deconditioning) remain unknown. One plausible explanation for the findings in this study is disuse atrophy. As the disease progresses and symptoms intensify, patients become locked into a downward spiral of breathlessness, leading to inactivity, and subsequent muscle deconditioning with the greatest effect on the muscles that are least used—that is, the quadriceps muscle. In comparison, the adductor pollicis muscle is continually used for activities of daily living, such as eating, grooming, and writing. This hypothesis is supported by previous studies (using volitional techniques) showing the unequal distribution of muscle weakness in patients with COPD, with the strength of the upper extremity muscles being relatively preserved compared with that of the lower extremity muscles. 19,20

Apart from distribution of muscle weakness, deconditioning shares many similarities with COPD in its effects on the morphological and metabolic characteristics of skeletal muscle. Alterations in the distribution of muscle fibre type as a result of chronic inactivity are similar to those observed in patients with COPD, with a reduction in slow twitch type I fibres and an increase in fast twitch type II fibres. 22 In addition, a reduction in oxidative metabolism is found in the quadriceps muscle of subjects with deconditioning, 23 as well as in patients with COPD. 24 Consistent with our hypothesis, skeletal muscles not primarily used for locomotion (such as tibialis anterior and deltoid) do not show reduced oxidative capacity in COPD. 25-28 In a recent comprehensive review of the literature Franssen and colleagues compared the alterations in peripheral skeletal muscle function, muscle morphology, and energy metabolism in COPD with those of reduced physical activity. 27 The authors concluded that “deconditioning of peripheral muscles is very likely to be an important contributor to the alterations in peripheral skeletal muscles that occur in patients with COPD”. Despite the similarities in skeletal muscle abnormalities between reduced activity and chronic lung disease, atrophy in disuse principally affects type I fibres whereas type IIx fibres seem to be preferentially affected in COPD 29; however, there are published data demonstrating type II atrophy in disuse 30-32 and type I atrophy in COPD. 33

Our hypothesis is dependent on the assumption that the physical activity level of our cohort of COPD patients was reduced compared with our healthy elderly group. We believe this to be a reasonable assumption as published data confirm that activity levels are decreased in patients with COPD compared with age matched healthy controls. 31 33 Furthermore, if our hypothesis that detraining is a significant contributor to skeletal muscle weakness is correct, exercise training would be expected to improve muscle function. It is now well accepted that pulmonary rehabilitation improves exercise capacity and quality of life in COPD without changes in lung function. 34 Exercise training has been shown to increase volitional and non-volitional quadriceps strength, 35 36 to increase skeletal muscle oxidative capacity, and reduce lactic acidosis. 37 Another treatment that “trains” muscles—neuromuscular electrical stimulation—has been shown to improve quadriceps strength, exercise capacity, and quality of life. 38

An alternative explanation for the results of this study is that a systemic process does operate but preferentially affects the proximal muscles; steroid myopathy, although excluded as a cause in the present study, is an example of such a process. This is supported by work by Gosselink and colleagues 4 who reported that handgrip and elbow flexion force are less affected than shoulder abduction or knee extension force in patients with COPD using volitional techniques. Why a systemic inflammatory process (or, indeed, steroid myopathy) should have a predilection for proximal muscles is not known. A possible explanation is that some myopathies preferentially affect certain fibre types; necropsy data suggest that the adductor pollicis muscle, although containing both fibre types, is largely composed of type 1 fibres whereas the quadriceps muscle consists of 43% type 1 fibres and 57% type 2 fibres. 39 Non-volitional assessment of a large proximal upper limb muscle and a small distal lower limb muscle would help to confirm or refute this hypothesis, but well established reproducible techniques are not currently available. In summary, the strength of the adductor pollicis muscle (and the diaphragm) is normal in patients with stable COPD despite the presence of significant weakness of the quadriceps. This observation supports the hypothesis that deconditioning and disuse atrophy are important in the development of muscle weakness in patients with COPD, at least in those who are stable without recent weight loss. However, a systemic process preferentially affecting the proximal muscles cannot be excluded. Further studies are required to delineate whether disuse alone is a sufficient condition, or whether interaction with systemic factors is also required.

Authors’ affiliations
W D-C Man, M G G Soliman, D Nikoletou, M L Harris, G F Rafferty, N Mustfa, J Moxham, Respiratory Muscle Laboratory, Guy’s, King’s and St Thomas’ School of Medicine, King’s College Hospital, London, UK
M I Polkey, Royal Brompton Hospital, London, UK
William Man is a Clinical Research Training Fellow of the Medical Research Council (UK).

REFERENCES
Prophylactic itraconazole may decrease the rate of invasive fungal infection in allogeneic haematopoietic stem cell transplant recipients

Invades fungal infections account for the majority of deaths due to infection in patients following allogeneic hematopoietic stem cell transplants, although toxicity secondary to antifungal agents and the emergence of resistant fungal strains are presenting clinical dilemmas. This multicenter randomized open label trial compared prophylactic itraconazole (intravenous and oral) with fluconazole (intravenous and oral) in 140 patients over the age of 13 on the first day after transplantation and continued for 100 days with follow up until day 180 after transplantation or death. The primary end point was the incidence of invasive fungal infection and the secondary end points were the rates of superficial fungal infection, adverse events secondary to the study drug, mortality from fungal infection, and survival. The incidence of invasive fungal infection was significantly lower in the patients given prophylactic itraconazole with lower though non-significant differences in mortality. Overall, the incidence of invasive fungal infection was high in this study compared with that of earlier studies. This was attributed both to the high use of corticosteroids (85%) which is associated with an increased risk of fungal infection and the generally increasing incidence reported throughout transplant centres in the United States. The safe and effective use of itraconazole in patients undergoing allogeneic hematopoietic stem cell transplantation may represent an important advance in the prevention of possibly fatal invasive fungal infection, although gastrointestinal side effects were significantly higher in patients treated with itraconazole.

S Doffman
Specialist Registrar, The Whittington Hospital, London, UK
sarh.doffman@hotmail.com

LUNG ALERT